Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02985554
Title Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Chicago
Indications

hematologic cancer

Therapies

Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.